Neuro-people doing cellular/circuit/synaptic/translational research on ALS and acute brain injuries using viruses, microscopes, immunology and biochemistry.
We are grateful to the Deutsche Forschungsgemeinschaft for funding the cooperative DFG/NRN project on reverse translation of Tofersen treatment in ALS. We are therefore looking for a new graduate student!
Thrilled that my lab's second paper is published today
@PNASNews! 🥳 We used spatial transcriptomics to investigate axial-level and sex differences in the molecular and cellular organization of the mouse spinal cord, as well as alterations in neuropathic pain.
https://t.co/MSsbdY3aqL
Today I am sharing a new preprint and accompanying blog post. Hundreds of published papers include impossible western blots showing protein expression in cell lines that have deleted or mutated genes. These clumsy mistakes are widespread and repeated by LLMs.
I am grateful to the member of the European Neurotrauma Organization for the election to the ENO Board. I will serve at the best of my abilities with the goal to promote young investigators, support neurotrauma research and make an impact on the care of patients. Thank you all!
Tesla in the US builds flying cars. Europe makes sure plastic bottle caps stay attached that you can hardly drink. While this is exaggerated to compare, unfortunately, I think the joke captures a serious problem.
For more than 10 years, we have been talking about innovation, startups and making Europe competitive. Yet how many new global technology leaders have we created, especially in Germany? We have excellent scientists, engineers and ideas. So why are we falling behind?
From my experience in science and biotech, one of the biggest problems is bureaucracy. We control almost every experiment, every purchase, every decision of a scientist. Endless approvals, regulations and administrative procedures. All of this costs time, money and, most importantly, takes away the freedom to be creative.
How can we compete with the US or China when building the same thing takes us much longer and costs several times more? I think we need to start where innovation begins: basic research. Give scientists freedom, responsibility and resources. Judge them by what they achieve rather than how many procedures they follow. Of course, we need rules and accountability. But we have to stop treating every scientist as someone who cannot be trusted. We cannot create an innovative Europe by regulating every step of innovation.
@AdrianoAguzzi I knew a professor who had his two rottweilers in his office all the time. meetings with him were short, and never exceeding the allowed time.
BREAKING NEWS
The 2026 #NobelPrize in Physiology or Medicine has been awarded to Karl Deisseroth, Peter Hegemann and Georg Nagel “for their discoveries concerning light-gated ion channels and optogenetics.”
Should one target C3 or CD14 to treat acute traumatic brain injury in polytrauma patients? Well, it may depend on where the injury actually is. C3 and CD14 are differentially required for neuroinflammation depending on the brain structure: doi: 10.1007/00011-026-02367-7
In the acute phase of polytrauma, complement cascade is dramatically activated. The brain is substantially affected. What happens if C3 and or CD14 are genetically absent?